The Third Consensus Conference on the treatment of aplastic anemia (Q37880645)

24 August 2017

title

The Third Consensus Conference on the treatment of aplastic anemia (English)

1 reference

24 August 2017

Seiji Kojima

1

1 reference

24 August 2017

Shinji Nakao

2

1 reference

24 August 2017

Neal Young

3

1 reference

24 August 2017

Andrea Bacigalupo

4

1 reference

24 August 2017

Gerard Gerard

5

1 reference

24 August 2017

Naoto Hirano

6

1 reference

24 August 2017

Jaroslaw Maciejewski

7

1 reference

24 August 2017

Joachim Deeg

8

1 reference

24 August 2017

Judith Marsh

9

1 reference

24 August 2017

Feng-Kui Zhang

10

1 reference

24 August 2017

Jong Wook Lee

11

1 reference

24 August 2017

Keiya Ozawa

12

1 reference

24 August 2017

publication date

27 May 2011

1 reference

International Journal of Hematology

24 August 2017

published in

1 reference

24 August 2017

volume

93

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

832-837

1 reference

Current concepts in the pathophysiology and treatment of aplastic anemia

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Aplastic anemia: pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Autoantibodies frequently detected in patients with aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Whole genome scanning as a cytogenetic tool in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0873-0

Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA

21 January 2018

1 reference

12 December 2020

Clinical impact of HLA-DR15, a minor population of paroxysmal nocturnal haemoglobinuria-type cells, and an aplastic anaemia-associated autoantibody in children with acquired aplastic anaemia

1 reference

12 December 2020

Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan

1 reference

12 December 2020

Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapiant

1 reference

12 December 2020

Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT rando

1 reference

12 December 2020

Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia

1 reference

12 December 2020

Comparison of matched-sibling donor BMT and unrelated donor BMT in children and adolescent with acquired severe aplastic anemia

1 reference

12 December 2020

Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party

1 reference

12 December 2020

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial

1 reference

12 December 2020

Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients

1 reference

12 December 2020

High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial

1 reference

12 December 2020

Progressive telomere shortening in aplastic anemia

1 reference

12 December 2020

Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia

1 reference

12 December 2020

Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation

1 reference

12 December 2020

10.1007/S12185-011-0873-0

Identifiers

DOI

1 reference

24 August 2017

1 reference